Who is sponsoring NCT03184935?

NCT03184935 is sponsored by Sclnow Biotechnology Co., Ltd..

What drugs are being tested in NCT03184935?

Interventions in NCT03184935: Allogeneic umbilical cord mesenchymal stem cells, Decitabine.

What condition does NCT03184935 study?

NCT03184935 studies Myelodysplastic Syndromes.

Is NCT03184935 still recruiting?

NCT03184935 is currently suspended. Last updated 14 May 2025.

Last reviewed 2025-05-14 · How we verify

NCT03184935

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Research for Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-MDS) in the Treatment of Myelodysplastic Syndrome (MDS)

Suspended Phase 1, PHASE2 Last updated 14 May 2025

What this trial tests

Phase 1, PHASE2 trial testing Allogeneic umbilical cord mesenchymal stem cells in Myelodysplastic Syndromes in 40 participants. Suspended.

Timeline

31 December 2025

Primary endpoint
30 June 2026

31 December 2026

Quick facts

Lead sponsor	Sclnow Biotechnology Co., Ltd.
Phase	Phase 1, PHASE2
Status	Suspended
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	40
Start date	31 December 2025
Primary completion	30 June 2026
Estimated completion	31 December 2026
Sites	1 location across China

Drugs / interventions tested

Allogeneic umbilical cord mesenchymal stem cells — full drug profile →
Decitabine (decitabine) — full drug profile →

Conditions studied

Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →

Sponsor

Sclnow Biotechnology Co., Ltd. — full company profile →

Who can join

Adults 60 to 85, any sex, with Myelodysplastic Syndromes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purposes of the study is to determine the safety and efficacy of human umbilical cord mesenchymal stem cells (hUC-MSC) in treating Myelodysplastic Syndrome patients.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Stromal cells in the tumor microenvironment: accomplices of tumor progression?
Zhao Y, Shen M, Wu L, Yang H, et al · · 2023 · cited 271× · PMID 37666813 · DOI 10.1038/s41419-023-06110-6
Mesenchymal stem/stromal cells in cancer therapy.
Lan T, Luo M, Wei X. · · 2021 · cited 251× · PMID 34789315 · DOI 10.1186/s13045-021-01208-w
Therapeutic Potential of Mesenchymal Stem Cells for Cancer Therapy.
Hmadcha A, Martin-Montalvo A, Gauthier BR, Soria B, et al · · 2020 · cited 241× · PMID 32117924 · DOI 10.3389/fbioe.2020.00043
Mesenchymal stem cells and cancer therapy: insights into targeting the tumour vasculature.
Aravindhan S, Ejam SS, Lafta MH, Markov A, et al · · 2021 · cited 55× · PMID 33685452 · DOI 10.1186/s12935-021-01836-9
The Role of Mesenchymal Stem Cells in Modulating the Breast Cancer Microenvironment.
Zhang L. · · 2023 · cited 17× · PMID 38135917 · DOI 10.1177/09636897231220073
Harnessing the Therapeutic Potential of Mesenchymal Stem Cells in Cancer Treatment.
Kangari P, Salahlou R, Vandghanooni S. · · 2024 · cited 4× · PMID 39494266 · DOI 10.34172/apb.2024.052
Mesenchymal Stem Cells in Myelodysplastic Syndromes and Leukaemia.
Eroz I, Kakkar PK, Lazar RA, El-Jawhari J. · · 2024 · cited 1× · PMID 39200142 · DOI 10.3390/biomedicines12081677
Mesenchymal Stromal Cells: Bridging the Gaps in Hematologic Disease Therapy.
Zhao X, Ming X, Wu J, Zhu X, et al · · 2026 · PMID 41254448 · DOI 10.1007/s12015-025-11011-6

Verify or expand the search:

Other trials of Allogeneic umbilical cord mesenchymal stem cells

Trials testing the same drug.

NCT06147986 — Evaluate the Efficacy and Safety of Allogeneic Umbilical Cord Mesenchymal Stem Cells As an Add-On Treatment for Acute ST · Phase 2 · recruiting
NCT05532943 — Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis · Phase 1, PHASE2 · recruiting
NCT05501418 — Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With COVID-19 · Phase 1, PHASE2 · unknown
NCT04056819 — Evaluate the Safety and Explore Efficacy of Umbilical Cord Mesenchymal Stem Cells in Acute Myocardial Infarction · Phase 1 · completed

Other recruiting trials for Myelodysplastic Syndromes

Currently open trials in the same condition.

NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
NCT06303193 — Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or · Phase 1, PHASE2 · recruiting
NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
NCT07283900 — Ascorbate in Myelodysplastic Syndrome · Phase 2 · recruiting
NCT06487247 — HEME Home Transfusion Program · NA · recruiting

Other Sclnow Biotechnology Co., Ltd. trials

Trials by the same sponsor.

NCT03186456 — The Safety and Efficacy of Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ACI) in the Treatment of Acute Cereb · Phase 1 · suspended
NCT06589271 — SCLife®-LDD hUC-MSCs Injection Therapy for Patients With Lumbar Intervertebral Disc Degeneration · Phase 1 · suspended
NCT03378414 — Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia · Phase 2 · not yet recruiting
NCT06503471 — SCLife®-UT hUC-MSCs Advanced Therapy Medicinal Products (hUC-MSCs ATMPs) for Patients With Thin Endometrial Infertility · Phase 1 · suspended
NCT03180463 — The Study of Early Stage Osteonecrosis of Femoral Head With Human Umbilical Cord Mesenchymal Stem Cells (19#iSCLife®-ONF · Phase 1, PHASE2 · suspended

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03184935 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sclnow Biotechnology Co., Ltd.
Last refreshed: 14 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03184935.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing